Chronic graft-versus-host disease (chronic GVHD) is a long-term immune-mediated complication after allogeneic hematopoietic stem cell transplantation in which donor immune cells attack recipient tissues.
Interim results from the ABC phase 1/2b trial show a calcineurin inhibitor-free GVHD prevention regimen combining posttransplant cyclophosphamide, bortezomib, and abatacept achieved low GVHD rates and favorable survival outcomes. The approach enables earlier introduction of posttransplant maintenance therapies while reducing toxicity associated with conventional immunosuppressants.
Syndax Pharmaceuticals announced a collaboration to expand global access to Revuforj while reporting strong commercial performance for its two marketed products, with Revuforj generating $125 million and Niktimvo $152 million in the first 11 months of sales.
Researchers developed BIOPREVENT, an AI-based tool that predicts chronic graft-versus-host disease and transplant-related mortality in stem cell and bone marrow transplant patients by analyzing blood biomarkers and clinical data collected 90-100 days post-transplant.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06458127 |
Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease |
ACTIVE_NOT_RECRUITING | NA |
| NCT05509582 |
Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias |
WITHDRAWN | PHASE2 |
| NCT05502783 |
Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias |
TERMINATED | PHASE2 |
| NCT04294641 |
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease |
COMPLETED | PHASE2 |
| NCT04146207 |
SHR0302 and Steroid As First Line Therapy for Chronic GVHD |
COMPLETED | EARLY_PHASE1 |
| NCT02611180 |
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease |
ACTIVE_NOT_RECRUITING | |
| NCT01937468 |
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT01106833 |
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) |
COMPLETED | PHASE2/PHASE3 |
